Methylprednisolone acetate and Vimpat drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Methylprednisolone acetate (methylprednisolone acetate) and Vimpat (lacosamide). Common drug interactions include hepatic enzyme increased among females and hypertransaminasaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Methylprednisolone acetate and Vimpat. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Methylprednisolone acetate?

Methylprednisolone acetate has active ingredients of methylprednisolone acetate. eHealthMe is studying from 2,816 Methylprednisolone acetate users. Check the latest studies of Methylprednisolone acetate.

What is Vimpat?

Vimpat has active ingredients of lacosamide. It is often used in epilepsy. eHealthMe is studying from 20,831 Vimpat users. Check the latest studies of Vimpat.



On Jul, 17, 2026

15 people who take Methylprednisolone acetate and Vimpat together, and have interactions are studied.

Methylprednisolone acetate and Vimpat drug interactions.

What are the common drug interactions of Methylprednisolone Acetate and Vimpat, by gender? *:

female:

  1. Hepatic enzyme increased
  2. Hypernatraemia (an abnormally high plasma concentration of sodium ions)
  3. Iron deficiency
  4. Hypochloraemia (electrolyte disturbance in which there is an abnormally low level of the chloride ion in the blood)
  5. Alanine aminotransferase increased
  6. Ascites (accumulation of fluid in the abdominal cavity)
  7. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  8. Leukocytosis (increased white blood cells)
  9. Leukopenia (less number of white blood cells in blood)
  10. Bile duct stone

male:

  1. Hypertransaminasaemia
  2. Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system)
  3. Hepatotoxicity (chemical-driven liver damage)

What are the common drug interactions of Methylprednisolone Acetate and Vimpat, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Hepatic enzyme increased
  2. Hypernatraemia (an abnormally high plasma concentration of sodium ions)
  3. Iron deficiency
  4. Hypochloraemia (electrolyte disturbance in which there is an abnormally low level of the chloride ion in the blood)
  5. Alanine aminotransferase increased
  6. Ascites (accumulation of fluid in the abdominal cavity)
  7. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  8. Leukocytosis (increased white blood cells)
  9. Leukopenia (less number of white blood cells in blood)
  10. Bile duct stone

40-49:

n/a

50-59:

n/a

60+:

  1. Hypertransaminasaemia
  2. Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system)
  3. Hepatotoxicity (chemical-driven liver damage)

What are the existing conditions these people have? *

  1. Arrhythmias (irregular heartbeat): 13 people, 86.67%
  2. Stress And Anxiety: 13 people, 86.67%
  3. Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 13 people, 86.67%
  4. Sepsis (a severe blood infection that can lead to organ failure and death): 13 people, 86.67%
  5. Pneumonia: 13 people, 86.67%
  6. Hypovitaminosis (any of several diseases caused by deficiency of one or more vitamins): 13 people, 86.67%
  7. Mineral Deficiency (lack of mineral): 13 people, 86.67%
  8. Pain: 12 people, 80.00%
  9. Malabsorption (a state arising from abnormality in absorption of food nutrients across the gastrointestinal (gi) tract): 11 people, 73.33%
  10. Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 11 people, 73.33%

* Approximation only. Some reports may have incomplete information.

Do you take Methylprednisolone acetate and Vimpat?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Methylprednisolone acetate and Vimpat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Methylprednisolone acetate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Vimpat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Methylprednisolone acetate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Vimpat and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on methylprednisolone acetate and lacosamide (the active ingredients of Methylprednisolone acetate and Vimpat, respectively), and Methylprednisolone acetate and Vimpat (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: